HomeALKS • NASDAQ
Alkermes Plc
$25.70
After Hours:
$25.70
(0.00%)0.00
Closed: Oct 31, 4:03:34 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$26.31
Day range
$25.67 - $26.50
Year range
$22.07 - $32.88
Market cap
4.16B USD
Avg Volume
1.95M
P/E ratio
13.11
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Sep 2024Y/Y change
Revenue
378.14M-0.73%
Operating expense
210.29M-8.67%
Net income
92.38M93.44%
Net profit margin
24.4394.82%
Earnings per share
0.7314.06%
EBITDA
111.73M3.59%
Effective tax rate
15.82%
Total assets
Total liabilities
(USD)Sep 2024Y/Y change
Cash and short-term investments
908.86M2.22%
Total assets
2.16B-5.44%
Total liabilities
863.18M-6.55%
Total equity
1.29B
Shares outstanding
161.80M
Price to book
3.29
Return on assets
12.01%
Return on capital
15.82%
Net change in cash
(USD)Sep 2024Y/Y change
Net income
92.38M93.44%
Cash from operations
81.59M-18.17%
Cash from investing
-109.33M8.40%
Cash from financing
-111.11M-7,190.87%
Net change in cash
-138.86M-667.84%
Free cash flow
31.74M-63.37%
About
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
Founded
1987
Employees
2,100
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu